JP2023533314A5 - - Google Patents

Info

Publication number
JP2023533314A5
JP2023533314A5 JP2023501163A JP2023501163A JP2023533314A5 JP 2023533314 A5 JP2023533314 A5 JP 2023533314A5 JP 2023501163 A JP2023501163 A JP 2023501163A JP 2023501163 A JP2023501163 A JP 2023501163A JP 2023533314 A5 JP2023533314 A5 JP 2023533314A5
Authority
JP
Japan
Prior art keywords
approximately
amount
optionally
mannitol
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023501163A
Other languages
English (en)
Japanese (ja)
Other versions
JP7868025B2 (ja
JP2023533314A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/040452 external-priority patent/WO2022010854A1/en
Publication of JP2023533314A publication Critical patent/JP2023533314A/ja
Publication of JP2023533314A5 publication Critical patent/JP2023533314A5/ja
Application granted granted Critical
Publication of JP7868025B2 publication Critical patent/JP7868025B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023501163A 2020-07-07 2021-07-06 (s)-4-(4-(4-(((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-4-イル)オキシ)メチル)ベンジル)ピペラジン-1-イル)-3-フルオロベンゾニトリルを含む医薬組成物及びそれを使用する方法 Active JP7868025B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063048998P 2020-07-07 2020-07-07
US63/048,998 2020-07-07
PCT/US2021/040452 WO2022010854A1 (en) 2020-07-07 2021-07-06 Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)m ethyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same

Publications (3)

Publication Number Publication Date
JP2023533314A JP2023533314A (ja) 2023-08-02
JP2023533314A5 true JP2023533314A5 (cg-RX-API-DMAC7.html) 2024-07-11
JP7868025B2 JP7868025B2 (ja) 2026-06-01

Family

ID=77338767

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501163A Active JP7868025B2 (ja) 2020-07-07 2021-07-06 (s)-4-(4-(4-(((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-4-イル)オキシ)メチル)ベンジル)ピペラジン-1-イル)-3-フルオロベンゾニトリルを含む医薬組成物及びそれを使用する方法

Country Status (22)

Country Link
US (2) US12472176B2 (cg-RX-API-DMAC7.html)
EP (2) EP4178548B1 (cg-RX-API-DMAC7.html)
JP (1) JP7868025B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230035598A (cg-RX-API-DMAC7.html)
CN (1) CN115867261B (cg-RX-API-DMAC7.html)
AU (1) AU2021305052A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023000248A2 (cg-RX-API-DMAC7.html)
CA (1) CA3184460A1 (cg-RX-API-DMAC7.html)
DK (1) DK4178548T3 (cg-RX-API-DMAC7.html)
ES (2) ES2988714T3 (cg-RX-API-DMAC7.html)
FI (1) FI4178548T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241162T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068476T2 (cg-RX-API-DMAC7.html)
IL (1) IL299657A (cg-RX-API-DMAC7.html)
LT (1) LT4178548T (cg-RX-API-DMAC7.html)
MX (1) MX2023000292A (cg-RX-API-DMAC7.html)
PL (1) PL4178548T3 (cg-RX-API-DMAC7.html)
PT (1) PT4178548T (cg-RX-API-DMAC7.html)
RS (1) RS66027B1 (cg-RX-API-DMAC7.html)
SI (1) SI4178548T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400374T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022010854A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120004860A (zh) * 2020-07-20 2025-05-16 江苏恒瑞医药股份有限公司 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
PY0323128A (es) 2002-09-10 2012-12-03 Pharmacia Italia Spa Formulacion sólida que comprende un compuesto de indolina, útil en el tratamiento de trastornos relacionados con proteina de quinasas
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
AU2016213879B2 (en) 2009-05-19 2017-11-16 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
CA2772275A1 (en) 2009-09-18 2011-03-24 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
SMT201900071T1 (it) 2011-07-28 2019-02-28 Rigel Pharmaceuticals Inc Nuove formulazioni di (trimetossifenilammino)pirimidinile
TWI782395B (zh) 2016-01-08 2022-11-01 美商西建公司 抗增生化合物,及其醫藥組合物及用途
JP7258009B2 (ja) * 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法
PL3796912T3 (pl) 2018-05-23 2023-09-11 Celgene Corporation Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego
IL278854B2 (en) 2018-05-23 2026-01-01 Celgene Corp Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile
CN108502097B (zh) 2018-05-24 2023-06-30 江苏科技大学 一种可开闭月池挡板装置
AU2020206692B2 (en) 2019-01-09 2025-03-27 Celgene Corporation Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same

Similar Documents

Publication Publication Date Title
JP2020143072A5 (cg-RX-API-DMAC7.html)
JP2009537538A5 (cg-RX-API-DMAC7.html)
JP2013523733A5 (cg-RX-API-DMAC7.html)
JP2018065876A (ja) ニロチニブと選択された共結晶体を含有する多成分結晶系
RU2015151938A (ru) Таблетируемый препарат (4'-трифторметилфенил)амида (z)-2-циано-3-гидрокси-бут-2-еноевой кислоты с улучшенной устойчивостью
AU2005211514B2 (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
AU2021101977A4 (en) Crystalline forms and processes of lenvatinib besylate
JP2024501247A5 (cg-RX-API-DMAC7.html)
JP2024530045A (ja) リナプラザングルレート塩酸塩の多形
JP2020502208A (ja) ベンゾイミダゾール誘導体を含む新規な製剤
KR20180066039A (ko) 아파티닙을 포함하는 약학적 조성물
JP2009517353A5 (cg-RX-API-DMAC7.html)
JP2023536667A5 (cg-RX-API-DMAC7.html)
JP2022516989A5 (cg-RX-API-DMAC7.html)
JP2022501328A (ja) スルホンアミド構造キナーゼ阻害剤の新規塩酸塩形態
JP2022553833A5 (cg-RX-API-DMAC7.html)
JP2022525102A5 (cg-RX-API-DMAC7.html)
CN107033094A (zh) 一种药物共晶的晶型及其制备方法和组合物
FI4178548T3 (fi) (s)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-yyli)-1-oksoisoindolin-4-yyl)oksi)metyyli)bentsyyli)piperatsin-1-yyli)-3-fluoribentsonitriiliä käsittäviä lääkekoostumuksia ja niiden käyttötapoja
WO2017125841A1 (en) Pharmaceutical compositions of teriflunomide
US20090030057A1 (en) Pharmaceutical composition of telmisartan
JP2019500385A (ja) モルホリン誘導体の塩、結晶形、その製造方法、これらを含む医薬組成物およびその用途
JP2019500385A5 (cg-RX-API-DMAC7.html)
CN101528696B (zh) 晶态s-(-)-氨氯地平无水己二酸盐及其制备方法
US20070116759A1 (en) Pharmaceutical compositions of telmisartan